文献速递母胎医学产科

胸腔羊膜腔分流术治疗胎儿胸腔积液及先天性肺病变的系统评价与荟萃分析

Thoracoamniotic shunting for fetal pleural effusion and congenital lung lesions: systematic review and meta-analysis.
PubMed 文献 · Ultrasound Obstet Gynecol · 2026-11-03

该系统评价纳入45项研究、1976例接受胸腔羊膜腔分流术(TAS)的胎儿,评估胎儿胸腔积液或先天性肺病变的围产结局。胸腔积液胎儿胎死率为8.3%,围产期死亡率为29.5%;先天性肺病变胎儿分别为6.6%和22.6%。分流管相关并发症和早产常见,水肿消退率在两组分别为63.3%和95.1%。

要点

  • TAS与产前胸腔减压相关,可能促进胸腔积液和水肿消退。
  • 胸腔积液胎儿围产期死亡率为29.5%,先天性肺病变为22.6%。
  • 分流管移位或功能障碍及未足月胎膜早破常见,需密切监测。

核心结论

  • TAS对胎儿胸腔积液或先天性肺病变可实现产前胸腔减压,可能促进积液和水肿消退。
  • 与历史数据间接比较提示TAS可能降低死亡率,但需标准化选择标准及前瞻性或多中心研究进一步明确获益与风险。

研究设计与样本

  • 系统评价与荟萃分析,检索MEDLINE、CINAHL、Cochrane CENTRAL、Web of Science、Scopus和EMBASE数据库,从建库至2025年11月6日。
  • 纳入45项研究,共1976例接受TAS的胎儿;采用Downs and Black量表进行质量与偏倚风险评估。
  • 采用单臂随机效应荟萃分析及广义线性混合效应模型生成合并比例及95%CI,异质性用Cochran Q和I2统计量评估。
  • 按主要诊断(胸腔积液或先天性肺病变)进行亚组分析。

主要发现

  • 胸腔积液胎儿胎死率8.3%(95%CI 5.8-11.6%,I2=18.1%),围产期死亡率29.5%(95%CI 26.4-32.7%,I2=27.7%)。
  • 先天性肺病变胎儿胎死率6.6%(95%CI 3.5-12.1%,I2=0%),围产期死亡率22.6%(95%CI 13.2-35.9%,I2=0%)。
  • 胸腔积液组分流管移位13.2%(95%CI 8.8-19.4%)、分流管阻塞或故障14.1%(95%CI 9.1-21.1%);先天肺病变组分别为10.2%(95%CI 4.3-22.3%)和8.6%(95%CI 2.8-23.4%)。
  • 胸腔积液组TAS后未足月胎膜早破19.3%(95%CI 13.8-26.4%)、<37周分娩64.3%(95%CI 58.1-70.2%);先天肺病变组分别为15.4%(95%CI 5.9-34.5%)和41.6%(95%CI 29.4-54.8%)。
  • 水肿胎儿中,胸腔积液组水肿消退率63.3%(95%CI 52.9-72.6%),先天肺病变组95.1%(95%CI 82.5-98.8%)。

临床怎么用

  • 对于 selected 胎儿胸腔积液或先天性肺病变,TAS可作为产前胸腔减压的干预选项,可能促进积液和水肿消退。
  • 术前应充分告知分流管移位、阻塞或故障及未足月胎膜早破、早产等风险。
  • 术后需密切监测分流管功能及妊娠并发症,尤其是早产和胎膜早破。

局限性

  • 结论基于单臂荟萃分析,缺乏对照,与历史数据比较为间接比较。
  • 需要标准化选择标准以及前瞻性和/或多中心研究来更好定义TAS的获益与风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To summarize reported outcomes associated with thoracoamniotic shunting (TAS) in fetuses with pleural effusion or congenital lung lesions. METHODS: We conducted a search across MEDLINE, CINAHL, Cochrane CENTRAL, Web of Science, Scopus, and EMBASE databases, from inception to 6 November 2025, for studies reporting the incidence of perinatal outcomes after TAS in pregnancies complicated by fetal pleural effusion or congenital lung lesions. Quality and risk-of-bias assessments were performed utilizing the Downs and Black scale. Single-arm random-effects meta-analyses with generalized linear mixed-effects models were performed to generate pooled proportions with 95% CI. Heterogeneity was assessed using Cochran's Q and quantified by the I2 statistic. Subgroup analyses were conducted according to the primary diagnosis (pleural effusion or congenital lung lesions). RESULTS: Overall, 45 studies, including 1976 fetuses that underwent TAS, were included in the systematic review. Among fetuses with pleural effusion, the pooled proportion of fetal death was 8.3% (95% CI, 5.8-11.6%) (I2 = 18.1%) and that of perinatal death was 29.5% (95% CI, 26.4-32.7%) (I2 = 27.7%). In cases of congenital lung lesion, the corresponding pooled proportions were 6.6% (95% CI, 3.5-12.1%) (I2 = 0%) and 22.6% (95% CI, 13.2-35.9%) (I2 = 0%), respectively. Shunt-related complications included shunt displacement (13.2% (95% CI, 8.8-19.4%) in cases of pleural effusion and 10.2% (95% CI, 4.3-22.3%) in cases of congenital lung lesion) and shunt obstruction or malfunction (14.1% (95% CI, 9.1-21.1%) and 8.6% (95% CI, 2.8-23.4%), respectively). Preterm prelabor rupture of membranes after TAS was reported in 19.3% (95% CI, 13.8-26.4%) of cases of pleural effusion and 15.4% (95% CI, 5.9-34.5%) of cases of congenital lung lesion, and birth < 37 weeks occurred in 64.3% (95% CI, 58.1-70.2%) and 41.6% (95% CI, 29.4-54.8%) of cases, respectively. In hydropic fetuses, resolution of hydrops was achieved in 63.3% (95% CI, 52.9-72.6%) of cases of pleural effusion and 95.1% (95% CI, 82.5-98.8%) of cases of congenital lung lesion. CONCLUSIONS: TAS in fetuses with pleural effusion or congenital lung lesions is associated with prenatal thoracic decompression and may contribute to resolution of pleural effusion and hydrops in selected cases, with indirect comparisons with historical data suggesting a possible reduction in mortality. Standardized selection criteria and prospective and/or multicenter studies are needed to better define the benefits and risks of TAS. © 2026 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Callado GY, Arechvo A, Ruíz-Román R, et al. Thoracoamniotic shunting for fetal pleural effusion and congenital lung lesions: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2026. PMID: 42978153. doi:10.1002/uog.70345

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。